Disease modifying anti-rheumatic drug treatment cycles and rates of flare in juvenile idiopathic arthritis—a tale of Sisyphean endeavour?
In JIA patients requiring DMARD therapy, recurrent treatment withdrawal trials are common over follow-up, but relapse risk is high and remains so over successive trials. Permanent treatment withdrawal is therefore not a realistic goal for most patients with therapies currently available. Until biomarkers of permanent remission are developed, strategies to minimize both drug toxicity and the risk of disease flares in patients with recurrently active disease after medication withdrawal are required.
Authors
- Jane Munro (ORCID: https://orcid.org/0000-0003-3018-2194)
- William D Renton (ORCID: https://orcid.org/0000-0002-9631-4455)
- Jonathan Akikusa
- A. Cox (ORCID: https://orcid.org/0000-0002-5221-8517)
- Peter Gowdie
- Georgina Tiller (ORCID: https://orcid.org/0000-0001-5834-8833)
- Jo Buckle
- Roger C. Allen
- Emily Bugeja
Institutions
- The Royal Melbourne Hospital (AU)
- Royal Children's Hospital (AU)
- The University of Melbourne (AU)
- Monash Children’s Hospital (AU)
- Murdoch Children's Research Institute (AU)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1093/rheumatology/keaf321
- Citations
- 1
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77